Juno Therapeutics News Timeline Breakdown

JUNO -- USA Stock  

null 85.82  0.20  0.23%

This is yet another view into Juno Therapeutics filtered headlines to help investors concentrate on Juno Therapeutics noise-free news that matters. Some academic researchers believe in strong correlation between financial news and their impacts to the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Juno Therapeutics headlines in addition to utilizing other more conventional financial analysis modules. Please also check Risk vs Return Analysis.
Macroaxis News
September 2, 2018
Exercise or conversion by Sean Harper of 16109 shares of Amgen subject to Rule 16b-3 at MacroaxisInsider 
View Story
businessinsider News
September 21, 2018
Ontario becomes first province to provide public funding of TRESIBA for adults with diabetes mellitus at markets.businessinsider.com 
View Story
news
September 17, 2018
Glenmark Pharma gets final USFDA nod for menopause symptom relief drug at www.business-standard.com 
View Story
seekingalpha News
September 12, 2018
Gilead Sciences, Inc. CEO John Milligan at the Morgan Stanley 16th Annual Global Healthcare Conference ... at seekingalpha.com 
View Story
Macroaxis News
September 19, 2018
Acquisition by Brett Pletcher of tradable shares of Gilead Sciences subject to Rule 16b-3 at MacroaxisInsider 
View Story
news
September 25, 2018
Blackrock Inc. is the biggest holder of Gilead Sciences, Inc. at postanalyst.com 
View Story
news
September 4, 2018
Nutrien Ltd. is better stock pick than Gilead Sciences, Inc. at stocknewsgazette.com 
View Story
Macroaxis News
September 25, 2018
Sale by Stephen Sherwin of 2500 shares of Biogen at MacroaxisInsider 
View Story
news
September 11, 2018
Financially Devastating or Fantastic Garmin Ltd. , Biogen Inc. at stocknewsgazette.com 
View Story
reuters
September 17, 2018
Australian shares slip as trade war hits materials and energy stocks NZ flat at www.reuters.com 
View Story
news
September 25, 2018
Stanbic IBTC, 9 others trade N1.3trn shares in 8 months at newtelegraphonline.com 
View Story
fool News
September 6, 2018
Is this the greatest threat to the SPASX 200 bull market at www.fool.com.au 
View Story
news
September 12, 2018
Notable Stocks on the Run Celgene Corporation, , Baytex Energy Corp., at globalexportlines.com 
View Story
news
September 18, 2018
Andra AP fonden Acquires Shares of 120400 Celgene Co. at www.fairfieldcurrent.com 
View Story
news
September 21, 2018
Financially Devastating or Fantastic Celgene Corporation , Novartis AG at stocknewsgazette.com 
View Story
seekingalpha News
September 5, 2018
Will Revlimids Patent Protection Hold Up For Celgene at seekingalpha.com 
View Story
news
September 4, 2018
Shire plc Snapshot of Recent Traded Stock at www.talktraders.com 
View Story
news
September 18, 2018
Shire plc Rule 2.9 Announcement at globenewswire.com 
View Story
news
August 31, 2018
Equity Review Investors Keen on Shares of Shire plc as it Makes Headlines With Moves at www.thecoinguild.com 
View Story
Macroaxis News
September 25, 2018
Sale by Riley Wayne Joseph of 9700 shares of Vertex Pharmaceuticals at MacroaxisInsider 
View Story
Macroaxis News
September 5, 2018
Sale by Alfred Gilman of 800 shares of Regeneron Pharmaceuticals at MacroaxisInsider 
View Story
Macroaxis News
September 6, 2018
Exercise or conversion by Bienaime Jean Jacques of 1500 shares of BioMarin Pharmaceutical subject to Rule 16b-3 at MacroaxisInsider 
View Story
news
September 19, 2018
Point72 Asset Management LP Lowers Stake in BioMarin Pharmaceutical Inc. at www.fairfieldcurrent.com 
View Story

Current Sentiment - JUNO

Juno Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on Juno Therapeutics. What is your judgment towards investing in Juno Therapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Search macroaxis.com